Bridget Larkin

Bridget Larkin has worked in the biotechnology and pharmaceutical industry since 2008. Bridget began their career as a Postdoctoral Scholar and Graduate Student Researcher at Tufts University, where they studied immunology and T cell-based pathology during infection with the tropical parasite Schistosoma mansoni. In 2017, they began working as an Editor for Boston Professional Group Editing and as a Scientist for Kymera Therapeutics, where they established flow cytometry assays to monitor targeted protein degradation in cell lines and primary cells for high-throughput screening of compounds. From 2018 to 2021, Bridget worked as a Senior Scientist and Scientist at Pandion Therapeutics, and then as a Senior Scientist, Translational at Revitope. Bridget is currently employed as a Sr. Scientist II at Celsius Therapeutics.

Bridget Larkin attended Xavier University from 2004 to 2008, during which time they earned a Bachelor of Science degree in Biology, General. Bridget then attended Tufts University from 2008 to 2017, where they earned a Doctor of Philosophy degree in Immunology.